Eli Lilly Ownership
Who are the major shareholders and have insiders been buying or selling?
Recent Insider Transactions
| Date | Value | Name | Entity | Role | Shares | Max Price |
|---|---|---|---|---|---|---|
| 06 May 26 | SellCHF 12,276,092 | Lilly Endowment Inc. | Company | 15,828 | CHF 776.24 | |
| 07 Jan 26 | SellCHF 256,943,890 | Lilly Endowment Inc. | Company | 292,148 | CHF 890.02 | |
| 05 Jan 26 | SellCHF 1,195,643 | Lilly Endowment Inc. | Company | 1,390 | CHF 860.18 | |
| 29 Dec 25 | SellCHF 3,080,034 | Lilly Endowment Inc. | Company | 3,593 | CHF 857.23 | |
| 24 Dec 25 | SellCHF 2,457,911 | Lilly Endowment Inc. | Company | 2,869 | CHF 856.72 | |
| 25 Nov 25 | SellCHF 144,149,939 | Lilly Endowment Inc. | Company | 162,693 | CHF 897.21 | |
| 24 Nov 25 | SellCHF 122,910,075 | Lilly Endowment Inc. | Company | 142,307 | CHF 867.80 | |
| 21 Nov 25 | SellCHF 90,235,806 | Lilly Endowment Inc. | Company | 105,326 | CHF 862.79 | |
| 20 Nov 25 | SellCHF 31,464,265 | Lilly Endowment Inc. | Company | 37,148 | CHF 850.00 | |
| 19 Nov 25 | SellCHF 141,803,480 | Lilly Endowment Inc. | Company | 167,526 | CHF 849.60 | |
| 18 Nov 25 | SellCHF 49,825,014 | Lilly Endowment Inc. | Company | 60,213 | CHF 831.34 | |
| 17 Nov 25 | SellCHF 8,105,666 | Lilly Endowment Inc. | Company | 9,886 | CHF 820.59 | |
| 14 Nov 25 | SellCHF 145,802,267 | Lilly Endowment Inc. | Company | 178,295 | CHF 819.57 | |
| 13 Nov 25 | SellCHF 38,031,151 | Lilly Endowment Inc. | Company | 46,606 | CHF 817.22 | |
| 12 Nov 25 | SellCHF 245,933,263 | Lilly Endowment Inc. | Company | 305,000 | CHF 814.22 | |
| 11 Nov 25 | SellCHF 236,555,140 | Lilly Endowment Inc. | Company | 300,000 | CHF 799.11 | |
| 05 Nov 25 | SellCHF 166,742,437 | Lilly Endowment Inc. | Company | 219,474 | CHF 774.60 | |
| 04 Nov 25 | SellCHF 387,556 | Lilly Endowment Inc. | Company | 526 | CHF 736.80 | |
| 03 Nov 25 | SellCHF 215,316,337 | Lilly Endowment Inc. | Company | 300,000 | CHF 727.38 | |
| 31 Oct 25 | SellCHF 208,980,163 | Lilly Endowment Inc. | Company | 301,342 | CHF 698.41 | |
| 10 Oct 25 | SellCHF 2,527,472 | Lilly Endowment Inc. | Company | 3,658 | CHF 691.05 | |
| 09 Oct 25 | SellCHF 7,285,215 | Lilly Endowment Inc. | Company | 10,602 | CHF 691.00 | |
| 08 Oct 25 | SellCHF 69,107,766 | Lilly Endowment Inc. | Company | 101,420 | CHF 685.99 | |
| 07 Oct 25 | SellCHF 18,115,434 | Lilly Endowment Inc. | Company | 26,795 | CHF 676.08 | |
| 06 Oct 25 | SellCHF 109,013,897 | Lilly Endowment Inc. | Company | 161,183 | CHF 680.70 | |
| 03 Oct 25 | SellCHF 128,186,341 | Lilly Endowment Inc. | Company | 192,404 | CHF 673.93 | |
| 02 Oct 25 | SellCHF 73,920,361 | Lilly Endowment Inc. | Company | 112,596 | CHF 666.40 | |
| 01 Oct 25 | SellCHF 227,264,480 | Lilly Endowment Inc. | Company | 351,015 | CHF 665.18 | |
| 30 Sep 25 | SellCHF 69,207,221 | Lilly Endowment Inc. | Company | 113,694 | CHF 610.89 | |
| 19 Sep 25 | SellCHF 14,361,497 | Lilly Endowment Inc. | Company | 23,665 | CHF 607.96 | |
| 18 Sep 25 | SellCHF 64,564,343 | Lilly Endowment Inc. | Company | 106,626 | CHF 607.43 | |
| 15 Aug 25 | BuyCHF 398,353 | Lucas Montarce | Individual | 715 | CHF 557.14 | |
| 13 Aug 25 | BuyCHF 520,665 | Jacob Van Naarden | Individual | 1,000 | CHF 520.67 | |
| 13 Aug 25 | BuyCHF 402,525 | Ralph Alvarez | Individual | 758 | CHF 531.04 | |
| 12 Aug 25 | BuyCHF 512,403 | Daniel Skovronsky | Individual | 1,000 | CHF 512.40 | |
| 12 Aug 25 | BuyCHF 811,924 | Jon Erik Fyrwald | Individual | 1,565 | CHF 519.01 | |
| 12 Aug 25 | BuyCHF 849,902 | David Ricks | Individual | 1,632 | CHF 520.77 | |
| 12 Aug 25 | BuyCHF 60,592 | Gabrielle Sulzberger | Individual | 117 | CHF 517.88 | |
| 08 Aug 25 | BuyCHF 103,238 | Jamere Jackson | Individual | 200 | CHF 516.19 | |
| 24 Jul 25 | SellCHF 179,158,719 | Lilly Endowment Inc. | Company | 280,000 | CHF 642.45 |
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
| Owner Type | Number of Shares | Ownership Percentage |
|---|---|---|
| Private Companies | 7,152 | 0.000802% |
| State or Government | 882,959 | 0.099% |
| Individual Insiders | 1,521,180 | 0.171% |
| General Public | 92,982,955 | 10.4% |
| Institutions | 796,347,160 | 89.3% |
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
| Ownership | Name | Shares | Current Value | Change % | Portfolio % | |
|---|---|---|---|---|---|---|
| 91,881,150 | CHF 82.6b | -0.02% | 100.0% | |||
| 66,213,379 | CHF 59.5b | -0.68% | 0.84% | |||
| 53,361,774 | CHF 48.0b | 0% | 1.02% | |||
| 51,123,265 | CHF 45.9b | 0% | 32.06% | |||
| 46,815,845 | CHF 42.1b | -6.23% | 1.94% | |||
| 35,610,002 | CHF 32.0b | 0.7% | 1.1% | |||
| 24,197,631 | CHF 21.7b | 2.65% | 1.18% | |||
| 20,977,027 | CHF 18.9b | 0% | 1.08% | |||
| 20,191,864 | CHF 18.1b | 1.93% | 1.05% | |||
| 15,018,780 | CHF 13.5b | -6.2% | 1.32% | |||
| 13,427,061 | CHF 12.1b | 0.52% | 2.25% | |||
| 12,074,882 | CHF 10.9b | 0% | 0.78% | |||
| 11,115,589 | CHF 10.0b | 10.5% | 0.81% | |||
| 10,759,188 | CHF 9.7b | -13.8% | 8.27% | |||
| 9,309,440 | CHF 8.4b | 5.33% | 0.86% | |||
| 9,223,432 | CHF 8.3b | -0.46% | 5.99% | |||
| 8,878,833 | CHF 8.0b | -3.3% | 0.81% | |||
| 8,827,564 | CHF 7.9b | -0.09% | 1.08% | |||
| 6,029,267 | CHF 5.4b | 0.09% | 1.15% | |||
| 5,899,282 | CHF 5.3b | 2.43% | 0.77% | |||
| 5,426,474 | CHF 4.9b | -1.58% | 0.82% | |||
| 5,379,364 | CHF 4.8b | 1.62% | 1.03% | |||
| 5,352,135 | CHF 4.8b | -0.68% | 1.03% | |||
| 5,136,445 | CHF 4.6b | 9.17% | 0.79% | |||
| 5,073,419 | CHF 4.6b | -4.19% | 1.16% |
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/17 02:41 |
| End of Day Share Price | 2026/06/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eli Lilly and Company is covered by 53 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |